期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

降钙素原与急性胰腺炎 被引量：9

原文传递
导出
摘要 急性胰腺炎（AP）的死因可归结为早期的休克和继发的多器官功能障碍综合征（multiple organ dysfunction syndrome，MODS）及后期的胰腺、胰周严重感染及其并发症。寻找一种能够精确地预测AP严重程度和准确地预示胰腺坏死感染的标志物是诊治AP的主要课题之一。
作者 李红昌 吴旭波 雷若庆 张圣道
机构地区 上海交通大学医学院附属瑞金医院普通外科
出处 《中华胰腺病杂志》 CAS 2010年第4期293-295,共3页 Chinese Journal of Pancreatology
关键词 急性胰腺炎 降钙素原 多器官功能障碍综合征 胰腺坏死感染 严重感染 并发症 标志物 AP
分类号 R657.5 [医药卫生—外科学]
  • 相关文献

参考文献21

  • 1Balcl C, Sungurtekin H, Gurses E, et al. Usefulness of proealeitonin for diagnosis of sepsis in the intensive care unit. Grit Care, 2003,7 : 85 -90.
  • 2Meisner M, Lohs T, Huttemann E, et al. The plasma elimination rate and urinary secretion of procaleitonin in patients with normal and impaired renal function. Eur J Anaesthesiol,2001,18 :79-87.
  • 3Whang KT, Vath SD, Becker KL, et al. Procaleitonin and proinflammatory cytokine interactions in sepsis. Shock, 2000,14 : 73 -78.
  • 4Morgenthaler NG, Struck J, Chaneerelle Y, et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Horm Metab Res,2003,35:290-295.
  • 5Yonetci N, Sungurtekin U, Oruc N, et al. Is procalcitonin a reliable marker for the diagnosis of infected pancreatic necrosis? ANZ J Surg,2004,74:591-595.
  • 6殷常康.急性胰腺炎患者血清降钙素原与ARDS关系的研究[J].胰腺病学,2007,7(3):157-159. 被引量：3
  • 7刘晓利,杜斌,潘家绮,许莹,华宝来.降钙素原在全身炎症反应综合征鉴别诊断和监测中的作用[J].中国医学科学院学报,2005,27(1):48-52. 被引量：24
  • 8Kylanpaa-Back ML,Takala A, Kemppainen E, et al. Procalcitonin strip test in the early detection of severe acute pancreatitis. Br J Surg,2001,88 :222-227.
  • 9Hensel M, Volk T, Docke WD, et al. Hyperprocalcitonemia in patients with noninfectious SIRS and pulmonary dysfunction associated with cardiopulmonary bypass. Anesthesiology, 1998, 89:93-104.
  • 10Melzi D'Ederil GV, Merlini G, Finazzi S, et al. Procalcitonin is not a reliable marker for assessment of severity in acute panacreatitis without infenctious complications. Clin Chem ,2000,46:428-430.

二级参考文献23

  • 1Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med, 2001, 29(7):1303-1310.
  • 2Evans ME, Kortas KJ. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guideline. Infect Control Hosp Epidemiol, 1996, 17(6):356-359.
  • 3Snider RH, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Investig Med, 1997, 45(9):552-560.
  • 4American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med, 1992, 20(6):864-874.
  • 5Vincent JL, Moreno R, Takala J, et al. The SOFA score to describe organ dysfunction/failure. Intensive Care Med,1996, 22(7):707-710.
  • 6Oberhoffer M, Vogelsang H, Russwurm S, et al. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med, 1999, 37(3):363-368.
  • 7Hausfater P, Garric S, Ayed B, et al. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis,2002, 34(7):895-901.
  • 8Selberg O, Hecker H, Martin M, et al. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med, 2000, 28(8):2793-2798.
  • 9Yukioka H, Yoshida G, Kurita S, et al. Plasma proealcitonin in sepsis and organ failure. Ann Acad Med Singapore,2001, 30(5):528-531.
  • 10Brunkhorst FM, Heinz U, Forycki ZF. Kinetics of procalcitonin in iatroginic sepsis. Intensive Care Med, 1998, 24(8):888-892.

共引文献28

同被引文献77

引证文献9

二级引证文献79

中华胰腺病杂志
2010年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部